ESK-001 for Moderate to Severe Plaque Psoriasis Study in Kentucky (ONWARD1)
1/15/25 — This clinical trial will evaluate the effectiveness of ESK-001 in treating moderate to severe plaque psoriasis.
Tildrakizumab for Moderate to Severe Genital Psoriasis Study in NYC
1/15/25 — Phase 3 study to evaluate the efficacy and safety of subcutaneous Tildrakizumab in subjects with moderate to severe genital psoriasis.
Tildrakizumab for Moderate to Severe Genital Psoriasis Study in Kentucky
1/15/25 — Phase 3 study to evaluate the efficacy and safety of subcutaneous Tildrakizumab in subjects with moderate to severe genital psoriasis.
Ixekizumab and Tirzepatide for Plaque Psoriasis and Overweight Study in NYC
11/1 — Be part of our NYC study to explore the effects of Ixekizumab and Tirzepatide on individuals with plaque psoriasis and overweight.
Ixekizumab and Tirzepatide for Plaque Psoriasis and Overweight Study in Kentucky
9/30 — Join our Kentucky study to explore the effects of Ixekizumab and Tirzepatide on individuals with plaque psoriasis and overweight.
